[go: up one dir, main page]

ATE382630T1 - Moleküle, die sich in ausgewählten organen oder geweben in-vivo einfinden - Google Patents

Moleküle, die sich in ausgewählten organen oder geweben in-vivo einfinden

Info

Publication number
ATE382630T1
ATE382630T1 AT99250432T AT99250432T ATE382630T1 AT E382630 T1 ATE382630 T1 AT E382630T1 AT 99250432 T AT99250432 T AT 99250432T AT 99250432 T AT99250432 T AT 99250432T AT E382630 T1 ATE382630 T1 AT E382630T1
Authority
AT
Austria
Prior art keywords
organ
tissue
vivo
tissues
home
Prior art date
Application number
AT99250432T
Other languages
English (en)
Inventor
Erkki I Ruoslahti
Renata Pasqualini
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/526,710 external-priority patent/US5622699A/en
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of ATE382630T1 publication Critical patent/ATE382630T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99250432T 1995-09-11 1996-09-10 Moleküle, die sich in ausgewählten organen oder geweben in-vivo einfinden ATE382630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52670895A 1995-09-11 1995-09-11
US08/526,710 US5622699A (en) 1995-09-11 1995-09-11 Method of identifying molecules that home to a selected organ in vivo

Publications (1)

Publication Number Publication Date
ATE382630T1 true ATE382630T1 (de) 2008-01-15

Family

ID=27062186

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96250195T ATE195181T1 (de) 1995-09-11 1996-09-10 Moleküle, die sich in ausgewählten organen oder geweben invivo einfinden und verfahren zu ihrer identifizierung
AT99250432T ATE382630T1 (de) 1995-09-11 1996-09-10 Moleküle, die sich in ausgewählten organen oder geweben in-vivo einfinden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96250195T ATE195181T1 (de) 1995-09-11 1996-09-10 Moleküle, die sich in ausgewählten organen oder geweben invivo einfinden und verfahren zu ihrer identifizierung

Country Status (9)

Country Link
EP (3) EP0876611A1 (de)
JP (3) JP3900305B2 (de)
AT (2) ATE195181T1 (de)
AU (1) AU693723B2 (de)
CA (1) CA2204535C (de)
DE (3) DE69637395T2 (de)
ES (1) ES2299232T3 (de)
HK (1) HK1027820A1 (de)
WO (1) WO1997010507A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
SE9700291D0 (sv) 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
CA2283474A1 (en) * 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
WO1999013329A1 (en) * 1997-09-10 1999-03-18 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
EP1062232B1 (de) * 1998-03-13 2008-09-10 The Burnham Institute Zielsuchende verbindungen für verschiedene organe und gewebe
JP2002510709A (ja) * 1998-04-08 2002-04-09 ジー・ディー・サール・アンド・カンパニー 二重Ａｖｂ３及び転移関連受容体リガンド
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO2000014215A1 (de) * 1998-09-07 2000-03-16 Eberhard-Karls-Universität Tübingen Verfahren zur selektion von peptiden für zielgerichteten pharma- und markertransport und peptide damit entdeckt
DE19845251A1 (de) * 1998-09-07 2000-03-09 Univ Eberhard Karls Peptide für Pharmatargeting
US6528481B1 (en) * 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6303573B1 (en) 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
ATE363074T1 (de) 1999-09-14 2007-06-15 Xenoport Inc Substrate und screeningverfahren für transportproteine
WO2001023619A1 (en) 1999-09-29 2001-04-05 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US7037706B1 (en) 1999-09-29 2006-05-02 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
WO2001044300A2 (en) * 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Brain specific binding members
WO2001077145A2 (en) 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
EP1322755B1 (de) * 2000-09-08 2010-08-18 Board of Regents, The University of Texas System Durch phagendisplay identifizierte zielpeptide des menschen und der maus
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US7229757B2 (en) 2001-03-21 2007-06-12 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
CA2452923C (en) 2001-07-10 2012-02-07 Amersham Health As Peptide-based compounds for targeting integrin receptors
WO2003008968A2 (en) * 2001-07-19 2003-01-30 Signet Laboratories, Inc. Human tissue specific drug screening procedure
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
WO2003040693A2 (en) * 2001-11-08 2003-05-15 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
US7598341B2 (en) 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
CA2461223C (en) * 2004-03-16 2013-05-28 Stanley Phillips Apparatus for generating ozone and/or o1 using a high energy plasma discharge
CN101124243A (zh) 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
NZ569818A (en) 2005-12-16 2012-07-27 Catherine M Shachaf Diagnostic system for the detection and diagnosis of skin cancer
FI121959B (fi) * 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
JP5522717B2 (ja) * 2008-09-19 2014-06-18 国立大学法人佐賀大学 アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
EP2374002A1 (de) 2008-12-23 2011-10-12 GE Healthcare UK Limited Anwendung einer auf 99mtc-peptid basierenden verbindung als knochenmark-bildgebungsmittel
US10322189B2 (en) 2014-11-12 2019-06-18 University Of Mississippi Medical Center Kidney-targeted drug delivery systems
US11564991B2 (en) 2014-11-12 2023-01-31 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
EP3405209B1 (de) * 2016-01-19 2021-05-26 The University Of Western Australia Neuartige biomolekülkonjugate und verwendungen davon
JP6895460B2 (ja) * 2016-06-03 2021-06-30 アイメッド・バイオ・インコーポレイテッド 患者由来腫瘍スフェロイドを用いた抗体スクリーニング方法
US11248038B2 (en) 2019-03-29 2022-02-15 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE23169T1 (de) * 1983-07-21 1986-11-15 Scripps Clinic Res Synthetische polypeptide, die gehirnspezifischen mrnas translatierten proteinoidabschnitten entsprechen, sowie ihre anwendung fuer rezeptoren, methoden und diagnostik.
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
ATE174598T1 (de) * 1990-08-24 1999-01-15 Ixsys Inc Verfahren zur herstellung von oligonukleotiden mit regellosen codonen
AU8740491A (en) * 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides

Also Published As

Publication number Publication date
ES2299232T3 (es) 2008-05-16
DE69637395T2 (de) 2008-12-18
EP0773441B1 (de) 2000-08-02
EP0876611A1 (de) 1998-11-11
JP2007204483A (ja) 2007-08-16
HK1027820A1 (en) 2001-01-23
JPH10502674A (ja) 1998-03-10
DE69637395D1 (de) 2008-02-14
ATE195181T1 (de) 2000-08-15
CA2204535A1 (en) 1997-03-20
CA2204535C (en) 2002-11-12
DE69609585T2 (de) 2001-04-05
JP2003155296A (ja) 2003-05-27
WO1997010507A1 (en) 1997-03-20
EP0987275A2 (de) 2000-03-22
AU6973996A (en) 1997-04-01
DE69609585D1 (de) 2000-09-07
EP0987275B1 (de) 2008-01-02
JP3900305B2 (ja) 2007-04-04
EP0987275A3 (de) 2006-06-21
EP0773441A1 (de) 1997-05-14
AU693723B2 (en) 1998-07-02
DE773441T1 (de) 1999-03-04

Similar Documents

Publication Publication Date Title
ATE382630T1 (de) Moleküle, die sich in ausgewählten organen oder geweben in-vivo einfinden
EA200300845A1 (ru) Модифицированные антитела и способы применения
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
DE69637800D1 (de) Verbindungen zur Behandlung der ischaemischen Gewebe
CY1116124T1 (el) Χρησεις αντισωματων για αμινοφωσφολιπιδια για τη θεραπευτικη αγωγη καρκινου
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
WO2000032772A3 (en) Erythropoietic compounds
DE69821011D1 (de) Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
EP0845032A4 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
DK1007566T3 (da) Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
ATE417930T1 (de) Proteinkinase npk-110
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
WO2004078022A3 (en) Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
ATE291738T1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
WO2002034282A3 (en) Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
WO2004022104A3 (en) Foxp2 and uses thereof
ES2192419T3 (es) Material aislado que presenta un efecto anti-organotrofico.
ATE269897T1 (de) Methoden zur identifizierung und validierung von funktionellen zielen mittels intrameren oder in vivo selektion
EA200500594A1 (ru) Лечебно-косметические препараты для кожи и слизистых
MD1732F1 (en) Method of prognosticating the duodenal ulcerous disease evolution

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties